Rapport Therapeutics (RAPP) Income from Continuing Operations (2023 - 2026)
Rapport Therapeutics' (RAPP) quarterly Income from Continuing Operations came in at 143692000.0 in Q1 2026, up 98.82% year-on-year from 72271280.44 in Q1 2025, and up 2.65% on a QoQ basis from 147602000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Income from Continuing Operations data on file, last reported at 143692000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 98.82% year-over-year to 143692000.0 in Q1 2026; TTM through Mar 2026 was 474112000.0, a 96.13% increase from a year earlier, with the FY2025 full-year figure at 225322000.0, down 187.74% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 143692000.0, up from 147602000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for RAPP reached as high as 6411000.0 in Q2 2023 and fell as low as 12209361000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 1065252416.67 across 4 years, with a median of 19050500.0 in 2024.
- Across the five-year window, Income from Continuing Operations tumbled 79809.42% in 2025 and soared 98.82% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 13519000.0 in 2023, then sank by 47.79% to 19980000.0 in 2024, then plunged by 638.75% to 147602000.0 in 2025, then advanced by 2.65% to 143692000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 143692000.0 in Q1 2026, 147602000.0 in Q4 2025, and 139286000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Rapport Therapeutics | 1.94 Bn | 1.94 Bn | - | -143.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -143.69 Mn |
| Dec 31, 2025 | -147.60 Mn |
| Sep 30, 2025 | -139.29 Mn |
| Jun 30, 2025 | -43.53 Mn |
| Mar 31, 2025 | -12.21 Bn |
| Dec 31, 2024 | -19.98 Mn |
| Sep 30, 2024 | -17.54 Mn |
| Jun 30, 2024 | -18.12 Mn |
| Mar 31, 2024 | -15.28 Mn |
| Dec 31, 2023 | -13.52 Mn |
| Sep 30, 2023 | -8.71 Mn |
| Jun 30, 2023 | -6.41 Mn |